FGAM
VERV

Financial Gravity Asset Management’s Verve Therapeutics VERV Stock Holding History

Financial Gravity Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$34 – 1779
2024
Q1 		$34 Buy
3
+2
+200% +$27 ﹤0.01% 1072
2023
Q4 		$9 Buy
+1
New +$12 ﹤0.01% 1289

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Financial Gravity Asset Management's VERV Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 3 shares — an estimated $34 sold.

Financial Gravity Asset Management first reported a position in VERV in Q4 2023 and held it in 2 quarters. The position peaked at $34 in Q1 2024. 167 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 3 Verve Therapeutics shares in Q2 2024, an estimated $34.
  • Financial Gravity Asset Management first reported a position in Verve Therapeutics in Q4 2023 and held it in 2 quarters.
  • Financial Gravity Asset Management's Verve Therapeutics position peaked at $34 in Q1 2024.
  • 167 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.